Your browser doesn't support javascript.
loading
Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies.
Fares, Aline F; Li, Yao; Jiang, Mei; Brown, M Catherine; Lam, Andrew C L; Aggarwal, Reenika; Schmid, Sabine; Leighl, Natasha B; Shepherd, Frances A; Wang, Zhichao; Diao, Nancy; Wenzlaff, Angela S; Xie, Juntao; Kohno, Takashi; Caporaso, Neil E; Harris, Curtis; Ma, Hongxia; Barnett, Matthew J; Leal, Leticia Ferro; Fernandez-Tardon, G; Pérez-Ríos, Mónica; Davies, Michael P A; Taylor, Fiona; Schöttker, Ben; Brennan, Paul; Zaridze, David; Holcatova, Ivana; Lissowska, Jolanta; Swiatkowska, Beata; Mates, Dana; Savic, Milan; Brenner, Hermann; Andrew, Angeline; Cox, Angela; Field, John K; Ruano-Ravina, Alberto; Shete, Sanjay S; Tardon, Adonina; Wang, Ying; Le Marchand, Loic; Reis, Rui Manuel; Schabath, Matthew B; Chen, Chu; Shen, Hongbing; Ryan, Brid M; Landi, Maria Teresa; Shiraishi, Kouya; Zhang, Jie; Schwartz, Ann G; Tsao, Ming S.
Afiliação
  • Fares AF; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Division of Medical Oncology, Faculty of Medicine of São José do Rio Preto, São Paulo, Brazil.
  • Li Y; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
  • Jiang M; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical
  • Brown MC; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada.
  • Lam ACL; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada.
  • Aggarwal R; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada.
  • Schmid S; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada; Universitätsklinik für Medizinische Onkologie, Inselspital Bern, Bern, Switzerland.
  • Leighl NB; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada.
  • Shepherd FA; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada.
  • Wang Z; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Division of Pulmonary and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  • Diao N; Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA.
  • Wenzlaff AS; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Xie J; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Kohno T; Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
  • Caporaso NE; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Harris C; Laboratory of Human Carcinogenesis, Centre for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
  • Ma H; Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Barnett MJ; Public Health Sciences, Biostatistics Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Leal LF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • Fernandez-Tardon G; University Institute of Oncology of Asturias-Cajastur Social Programme, University of Oviedo, Oviedo, Spain; Health Research Institute of Asturias, Oviedo, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Oviedo, Spain.
  • Pérez-Ríos M; Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.
  • Davies MPA; Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Taylor F; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK; Weston Park Cancer Centre, Sheffield Teaching Hospital Foundation Trust, Sheffield, UK.
  • Schöttker B; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Network of Aging Research, Heidelberg University, Heidelberg, Germany.
  • Brennan P; Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
  • Zaridze D; N N Blokhin National Medical Research Centre of Oncology, Moscow, Russia.
  • Holcatova I; Institute of Public Health and Preventive Medicine and Department of Oncology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
  • Lissowska J; Department of Cancer Epidemiology and Prevention, M Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Swiatkowska B; Nofer Institute of Occupational Medicine, Lódz, Poland.
  • Mates D; National Institute of Public Health, Bucharest, Romania.
  • Savic M; Department of Thoracic Surgery, Clinical Center of Serbia, Belgrade, Serbia.
  • Brenner H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center, Heidelberg, Germany; National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany; German Cancer Consort
  • Andrew A; Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Cox A; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Field JK; Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Ruano-Ravina A; Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.
  • Shete SS; M D Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Tardon A; University Institute of Oncology of Asturias-Cajastur Social Programme, University of Oviedo, Oviedo, Spain; Health Research Institute of Asturias, Oviedo, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Oviedo, Spain.
  • Wang Y; American Cancer Society, Atlanta, GA, USA.
  • Le Marchand L; University of Hawai'i Cancer Centre, University of Hawai'i, Honolulu, HI, USA.
  • Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil; Life and Health Sciences Research Institute, Medical School, University of Minho, Braga, Portugal; Life and Health Sciences Research Institute-Biomaterials, Biodegradables and Biomimetics Research Group Associate Laborat
  • Schabath MB; H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Chen C; Program in Epidemiology, Cancer Prevention Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Shen H; Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Ryan BM; Laboratory of Human Carcinogenesis, Centre for Cancer Research, National Institutes of Health, Bethesda, MD, USA.
  • Landi MT; National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Shiraishi K; Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan; Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.
  • Zhang J; Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Schwartz AG; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Tsao MS; Princess Margaret Cancer Centre and University Health Network, University of Toronto, Toronto, ON, Canada.
Lancet Public Health ; 8(9): e691-e700, 2023 09.
Article em En | MEDLINE | ID: mdl-37633678
BACKGROUND: The association between duration of smoking abstinence before non-small-cell lung cancer (NSCLC) diagnosis and subsequent survival can influence public health messaging delivered in lung-cancer screening. We aimed to assess whether the duration of smoking abstinence before diagnosis of NSCLC is associated with improved survival. METHODS: In this retrospective, pooled analysis of cohort studies, we used 26 cohorts participating in Clinical Outcomes Studies of the International Lung Cancer Consortium (COS-ILCCO) at 23 hospitals. 16 (62%) were from North America, six (23%) were from Europe, three (12%) were from Asia, and one (4%) was from South America. Patients enrolled were diagnosed between June 1, 1983, and Dec 31, 2019. Eligible patients had smoking data before NSCLC diagnosis, epidemiological data at diagnosis (obtained largely from patient questionnaires), and clinical information (retrieved from medical records). Kaplan-Meier curves and multivariable Cox models (ie, adjusted hazard ratios [aHRs]) were generated with individual, harmonised patient data from the consortium database. We estimated overall survival for all causes, measured in years from diagnosis date until the date of the last follow-up or death due to any cause and NSCLC-specific survival. FINDINGS: Of 42 087 patients with NSCLC in the COS-ILCCO database, 21 893 (52·0%) of whom were male and 20 194 (48·0%) of whom were female, we excluded 4474 (10·6%) with missing data. Compared with current smokers (15 036 [40·0%] of 37 613), patients with 1-3 years of smoking abstinence before NSCLC diagnosis (2890 [7·7%]) had an overall survival aHR of 0·92 (95% CI 0·87-0·97), patients with 3-5 years of smoking abstinence (1114 [3·0%]) had an overall survival aHR of 0·90 (0·83-0·97), and patients with more than 5 years of smoking abstinence (10 841 [28·8%]) had an overall survival aHR of 0·90 (0·87-0·93). Improved NSCLC-specific survival was observed in 4301 (44%) of 9727 patients who had quit cigarette smoking and was significant at abstinence durations of more than 5 years (aHR 0·87, 95% CI 0·81-0·93). Results were consistent across age, sex, histology, and disease-stage distributions. INTERPRETATION: In this large, pooled analysis of cohort studies across Asia, Europe, North America, and South America, overall survival was improved in patients with NSCLC whose duration of smoking abstinence before diagnosis was as short as 1 year. These findings suggest that quitting smoking can improve overall survival, even if NSCLC is diagnosed at a later lung-cancer screening visit. These findings also support the implementation of public health smoking cessation strategies at any time. FUNDING: The Alan B Brown Chair, The Posluns Family Fund, The Lusi Wong Fund, and the Princess Margaret Cancer Foundation.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil